Junshi Biosciences’ JS401 Receives NMPA Approval for Hyperlipidemia Clinical Trial
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biopharmaceutical company, has announced that it...
Jiangxi Jemincare Group Secures Exclusive Rights to Promote MabPharm’s Biosimilar CMAB007
Jiangxi Jemincare Group, a China-based healthcare company, has entered into a licensing agreement with fellow...
Zhejiang Dian Diagnostics Partners with Meituan for Digital Healthcare Services Expansion
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent medical diagnostics company based in China,...
Ocumension Therapeutics’ Zerviate NDA Accepted for Review by China’s NMPA
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that the National Medical...
Pfizer and Sinopharm Expand Partnership to Enhance Drug Distribution and Lifecycle Solutions
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced a strategic partnership with China-based Sinopharm...
Fosun Pharmaceutical’s FCN-159 Earns Breakthrough Therapy Designation for Histiocyte Tumors
The Center for Drug Evaluation (CDE) website has announced that Shanghai Fosun Pharmaceutical (Group) Co.,...
Aosaikang Pharmaceutical Receives NMPA Review for ASKC200 Liniment from Propella Therapeutics
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the National Medical Products Administration...
HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency
HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the...
Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion
PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed...
Huadong Medicine Reports 9.12% YOY Revenue Growth and 13.24% Increase in Net Profits for 2022
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has released its 2022...
BeiGene Launches LATAM Expansion with New Office in São Paulo, Brazil
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced its first...
Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment
US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its...
Convalife Pharmaceuticals’ Mefuparib Earns Orphan Drug Designation for Cholangiocarcinoma
Shanghai-based Convalife Pharmaceuticals has announced that it has received orphan drug designation (ODD) status from...
VintaBio Secures $64M Funding to Revolutionize Viral Vectors for Cell and Gene Therapy
New biotech VintaBio, founded in Philadelphia, Pennsylvania (United States), announces the appointment of CEO David...
Alebund Pharmaceuticals Secures $29M in Pre-Series C Funding and $116M Loan for R&D and Manufacturing
Shanghai-based Alebund Pharmaceuticals has announced the completion of a pre-Series C financing round worth RMB...
Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R/R DLBCL
Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China’s Overland Pharmaceuticals and Swiss...
Novartis’ Jakavi Secures NMPA Approval for Acute GVHD Treatment in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received a new indication...
Chengdu Hyperway Pharmaceuticals’ HBW-004285 Gets NMPA Tacit Approval for Pain Treatment
China-based Chengdu Hyperway Pharmaceuticals has announced receiving tacit clinical trial approval from the National Medical...
Shanghai Bio-Heart’s Iberis RDN System Meets Primary Endpoint in Iberis-HTN Study
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that its Iberis multi-electrode renal...
Grand Pharmaceutical’s APP13007 Achieves Clinical Endpoints in US Trials for Post-Operative Treatment
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that a Phase II clinical study...